Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
PENNINGTON, N.J., March 12, 2025 /PRNewswire/ — Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell…